A recent study revealed that hyperactive ERK1 is present in a large number of refractory prostate cancer cases and these cases also have frequent amplifications in the MAPK pathway, suggesting that MEK/ERK can be pharmacologically targeted to treat refractory metastatic prostate cancer [80]. This evidence concerns the gene MAP2K7 and prostate carcinoma.